UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 5, 2004
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | | 0-19700 | | 33-0266089 |
(State or other jurisdiction
of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
9360 Towne Centre Drive, Suite 110
San Diego, CA 92121
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (858) 552-2200
TABLE OF CONTENTS
2
ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.
The information in this Current Report is being furnished and shall be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934. The information contained in this Current Report and the exhibits attached hereto shall be incorporated by reference into any registration statement or other document filed with the Commission.
On June 5, 2004, Amylin Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that data from two of its exenatide pivotal studies presented at the American Diabetes Association’s 64th Annual Scientific Sessions (the “ADA”) in Orlando, Florida, show significant improvements in glucose control with associated weight loss in people with type 2 diabetes. A copy of this press release is attached as Exhibit 99.1.
On June 6, 2004, the Company issued a press release announcing that data from two exenatide studies to be presented at the ADA show improvements in glucose control and restored insulin response in people with type 2 diabetes. A copy of this press release is attached as Exhibit 99.2.
ITEM 7. EXHIBITS.
99.1 Press Release issued by the Company on June 5, 2004.
99.2 Press Release issued by the Company on June 6, 2004.
3
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AMYLIN PHARMACEUTICALS, INC. |
|
Dated: June 7, 2004 | By: | /S/ LLOYD A. ROWLAND | |
| | Lloyd A. Rowland |
| | Vice President, Legal, Secretary and General
Counsel |
4
99.1 Press Release issued by the Company on June 5, 2004.
99.2 Press Release issued by the Company on June 6, 2004.
5
